Literature DB >> 22189703

Functional VEGF haplotypes affect the susceptibility to hypertension.

V C Sandrim1, M R Luizon, T C Izidoro-Toledo, E B Coelho, H Moreno, J E Tanus-Santos.   

Abstract

We examined whether vascular endothelial growth factor (VEGF) polymorphisms (C-2578A, G-1154A and G-634C) are associated with hypertension, response to antihypertensive therapy and nitric oxide (NO) formation. Substudy 1 compared the distribution of VEGF genotypes and haplotypes in 178 patients with arterial hypertension (100 whites and 78 blacks) and 186 healthy controls (115 whites and 71 blacks). Substudy 2 compared the distribution of VEGF markers in 82 patients with controlled hypertension, 89 patients with resistant hypertension and 101 normotensive (NT) patients. In substudy 3, plasma nitrite/nitrate (NOx) levels were determined (chemiluminescence assay) in 64 NT subjects and 48 hypertensive (HTN) subjects, and the distribution of VEGF markers was compared in subjects having low NOx with subjects having high NOx. Although the substudy 1 showed no differences in genotypes or allele distributions for the three VEGF polymorphisms between NT and HTN subjects, the 'C-A-G' haplotype was more common in white NT subjects than in the white HTN subjects, and the 'C-A-C' haplotype was more frequent in black and white HTN subjects than in black and white NT subjects. The substudy 2 showed similar results, with no differences between responsive and resistant HTN subjects. The substudy 3 showed that the 'C-A-G' haplotype, which had a protective effect against hypertension, was significantly more common in subjects with higher NOx concentrations than in subjects with lower NOx concentrations. VEGF haplotypes are associated with hypertension, and the haplotype associated with normotension was more common in subjects with increased NO formation, possibly offering a mechanistic clue for our findings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189703     DOI: 10.1038/jhh.2011.110

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  3 in total

1.  In reply to: Enalapril and the VEGFA gene: personalized medicine in hypertension therapy.

Authors:  G H Oliveira-Paula; R Lacchini; J E Tanus-Santos
Journal:  Eur J Clin Pharmacol       Date:  2015-11-20       Impact factor: 2.953

2.  Preserved endothelial progenitor cell angiogenic activity in African American essential hypertensive patients.

Authors:  Seo Rin Kim; Alfonso Eirin; Sandra M S Herrmann; Ahmed Saad; Luis A Juncos; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Nephrol Dial Transplant       Date:  2018-03-01       Impact factor: 5.992

3.  Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril.

Authors:  G H Oliveira-Paula; R Lacchini; V Fontana; P S Silva; C Biagi; Jose E Tanus-Santos
Journal:  Eur J Clin Pharmacol       Date:  2015-05-24       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.